Quick Answer
Innate Pharma SA reported Net Income of -$58.10 million for fiscal year 2022.
Innate Pharma SA — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Net Income | — | — | -$58.10M -10.0% |
-$52.81M +17.5% |
-$63.98M -208.2% |
-$20.76M -780.8% |
| Total Assets | $111.06M -36.6% |
$175.19M -12.1% |
$199.29M -25.5% |
$267.50M -13.0% |
$307.42M -23.4% |
$401.36M -11.0% |
| R&D Expense | $51.98M -7.2% |
$56.02M +8.4% |
$51.66M +9.9% |
$47.00M -5.4% |
$49.71M -21.0% |
$62.90M -9.6% |
- Innate Pharma SA reported Net Income of -$58.10 million for fiscal year 2022.
- Innate Pharma SA showed a decrease of -10.0% in Net Income compared to the prior fiscal year.
- Innate Pharma SA reported Total Assets of $111.06 million for fiscal year 2024.
- Innate Pharma SA showed a decrease of -36.6% in Total Assets compared to the prior fiscal year.
- Innate Pharma SA reported R&D Expense of $51.98 million for fiscal year 2024.
- Innate Pharma SA showed a decrease of -7.2% in R&D Expense compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: